Structure Therapeutics (NASDAQ:GPCR) Trading Down 9.3%

Structure Therapeutics Inc. (NASDAQ:GPCRGet Free Report)’s stock price was down 9.3% during mid-day trading on Friday . The company traded as low as $46.60 and last traded at $46.85. Approximately 698,044 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 774,946 shares. The stock had previously closed at $51.64.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on GPCR shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 3rd. Lifesci Capital reissued an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Friday, May 10th. BMO Capital Markets raised their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, June 7th. Finally, JPMorgan Chase & Co. initiated coverage on Structure Therapeutics in a report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Buy” and an average price target of $85.25.

View Our Latest Stock Report on GPCR

Structure Therapeutics Price Performance

The business has a 50 day moving average of $40.55 and a 200 day moving average of $42.83. The firm has a market capitalization of $2.25 billion and a price-to-earnings ratio of -62.56.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. As a group, equities analysts predict that Structure Therapeutics Inc. will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brandywine Managers LLC raised its holdings in Structure Therapeutics by 9.2% during the fourth quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after acquiring an additional 1,007 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Structure Therapeutics by 17.8% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock valued at $589,000 after buying an additional 2,077 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Structure Therapeutics by 208.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock worth $177,000 after buying an additional 2,939 shares in the last quarter. Sectoral Asset Management Inc. acquired a new stake in Structure Therapeutics during the fourth quarter worth approximately $139,000. Finally, TrueMark Investments LLC grew its position in Structure Therapeutics by 13.5% during the first quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock worth $1,281,000 after buying an additional 3,562 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Stories

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.